Abrupt discontinuation deprescribing vs continued use: Lack of symptom control
It is very uncertain whether abrupt discontinuation deprescribing changes lack of symptom control compared with continued use (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Abrupt discontinuation deprescribing vs continued use Lack of symptom control · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years) It is very uncertain whether abrupt discontinuation deprescribing changes lack of symptom control compared with continued use (very low certainty). Deprescribing versus continuation of chronic proton pump inhibitor use in adults (2017) · Cochrane Headline outcomes only | RR 3.02 [1.74, 5.24] | 1 study · 105 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.